Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 5(64), 2020

DOI: 10.1128/aac.00012-20

Links

Tools

Export citation

Search in Google Scholar

ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae

Journal article published in 2020 by Michael R. Jacobs, Caryn E. Good, Andrea M. Hujer, Daniel D. Rhoads, Kristine M. Hujer, Susan D. Rudin, Kevin M. Krause, Robin Patel ORCID, Barry N. Kreiswirth, Laura J. Rojas, Roshan D’Souza, Richard C. White, Kevin Nguyen, Indresh Singh, Derrick E. Fouts ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Plazomicin was tested against 697 recently acquired carbapenem-resistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC 50 and MIC 90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of >32 mg/liter). Resistance was associated with rmtF -, rmtB -, or armA -encoded 16S rRNA methyltransferases in all except 1 isolate.